GSK’s Promacta And Amgen’s Nplate To Face Off In ITP Market
This article was originally published in The Pink Sheet Daily
Executive Summary
GlaxoSmithKline’s thrombocytopenia treatment for patients with idiopathic thrombocytopenic purpura will launch the week of Nov. 24.